A six-month, placebo-controlled trial of d -cycloserine co-administered with conventional antipsychotics in schizophrenia patients
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
d-Cycloserine, a partial agonist at the glycine site of the N-methyl-d-aspartate receptor, has demonstrated inconsistent efficacy for negative and cognitive symptoms of schizophrenia. The strongest evidence for efficacy has come from studies using d-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less.
To assess the efficacy for negative symptoms and cognitive impairment of d-cycloserine augmentation of conventional antipsychotics in a 6-month trial.
Fifty-five schizophrenia patients with prominent negative symptoms, treated with conventional antipsychotics, were randomly assigned to treatment with d-cycloserine 50 mg/day or placebo for 6 months in a double-blind, parallel group design.
Twenty-six subjects completed the 6-month trial; drop-out rates did not differ between treatment groups. d-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery. Serum d-cycloserine concentrations did not correlate with response of negative symptoms.
d-Cycloserine did not exhibit therapeutic effects in this trial, possibly reflecting the high drop-out rate, a narrow range of therapeutic serum concentrations, a modest magnitude of therapeutic effect for the selected outcome measures, or loss of efficacy over time. Because d-cycloserine is a partial agonist with relatively low affinity for the glycine site, the magnitude of potential therapeutic effect may be smaller than that achieved by the higher-affinity full agonists, glycine and d-serine.
- A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
Volume 179, Issue 1 , pp 144-150
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Schizophrenia Program, Massachusetts General Hospital, Boston, Mass., USA
- 2. Freedom Trail Clinic, 25 Staniford St, Boston, MA, 02114, USA
- 3. Harvard Medical School, Boston, Mass., USA
- 4. Bedford Veteran’s Affairs Medical Center, Boston University Medical School, Boston, Mass., USA
- 5. Lemuel Shattuck Hospital, Tufts Medical School, Boston, Mass., USA
- 6. Pediatric Neurology Service, Massachusetts General Hospital, Boston, Mass., USA
- 7. McLean Hospital, Belmont, Mass., USA
- 8. Biostatistics, Massachusetts General Hospital, Boston, Mass., USA